Mush­room mag­ic draws $80M in­jec­tion for Lon­don-based men­tal health start­up

6 years ago
Financing
Startups

Nim­bus founder Rosana Kapeller has a new com­pa­ny, with $50M and an eye on the ‘re­peatome’

6 years ago
Financing
Startups

FDA warns on safe­ty threat posed by 2 drugs ini­tial­ly backed by Trump for Covid-19 — fol­low­ing an emer­gency use ...

6 years ago
FDA+
Coronavirus

Lau­ra Shawver on why she came back af­ter an $88M wind­fall; Mor­phoSys taps Am­gen vet as CCO

6 years ago
Peer Review

Eli Lil­ly ex­ecs have been think­ing about the longterm ef­fects of the pan­dem­ic and dam­age con­trol. Here’s what they ...

6 years ago
People
R&D

Covid-19 roundup: Sanofi promis­es to bring re­com­bi­nant vac­cine ca­pac­i­ty to 1B+ while scal­ing up mR­NA man­u­fac­tur­ing

6 years ago
Coronavirus

GSK flash­es pos­i­tive da­ta for Tesaro drug that could be­come 7th ap­proved PD-(L)1

6 years ago
R&D

Take­da auc­tions off a $670M port­fo­lio of drugs and man­u­fac­tur­ing ops, get­ting clos­er to its $10B goal

6 years ago
Deals
Pharma

Lyn­parza im­proves sur­vival rate in prostate can­cer, giv­ing As­traZeneca and Mer­ck an­oth­er win on PARP front

6 years ago
R&D

FDA al­lows com­pounders to repack­age, com­bine propo­fol amid Covid-19

6 years ago
FDA+
Coronavirus

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

6 years ago
Bioregnum
R&D

An up­sized IPO? In this econ­o­my? Of course; Sofinno­va and Ab­b­Vie lead $38M Se­ries A for Parkin­son’s start­up

6 years ago
News Briefing

It's not de­vel­op­ing drugs that bind to RNA, or mor­ph­ing RNA in­to a ther­a­peu­tic — this Cam­bridge start­up has scored ...

6 years ago
Financing
Startups

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

6 years ago
People
Bioregnum

Covid-19 roundup: Har­vard sci­en­tist who in­vest­ed in Mod­er­na ear­ly be­comes a pan­dem­ic bil­lion­aire — and he's giv­ing ...

6 years ago
Coronavirus

Piv­otal da­ta ce­ment use of In­cyte, No­var­tis' rux­oli­tinib in dif­fi­cult-to-treat graft-ver­sus-host dis­ease

6 years ago
R&D
Pharma

Bain helps push Affini­vax to next stage with $120M round, as PhII da­ta loom on a lead ef­fort to do some­thing new in ...

6 years ago
Financing
R&D

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

6 years ago
R&D

De­posed BAR­DA chief blasts Trump ad­min­is­tra­tion on pro­mot­ing un­proven drugs as Covid-19 panacea: 'Science — not ...

6 years ago
People
Coronavirus

Ven­rock joins the biotech VC fundrais­ing game, toss­ing $447M in­to a $4.3B pot of new mon­ey

6 years ago
Financing

Analy­sis shows Swiss biotech in­dex out­shines Nas­daq coun­ter­part, but coro­n­avirus chal­lenges are uni­ver­sal

6 years ago
Financing
R&D

Over a year af­ter re­jec­tion, Im­munomedics emerges with po­ten­tial block­buster ap­proval

6 years ago
Pharma
FDA+

Big Phar­ma VC firms put $11M in seed funds be­hind can­cer start­up with bold vi­sion

6 years ago
Financing
Startups

EMA ap­proves Boehringer's sys­temic scle­ro­sis ther­a­py; No­var­tis' Kym­ri­ah wins RMAT sta­tus for fol­lic­u­lar lym­phoma

6 years ago
News Briefing
First page Previous page 833834835836837838839 Next page Last page
A service from the Financial Times